NEW YORK (GenomeWeb) – HelixBind will receive up to $2 million in funding from public-private partnership CARB-X to develop antibacterial products and rapid diagnostics, the company announced today.
The funding is for development of a culture-free diagnostic platform called RaPID and the first test to be implemented on the platform, a bloodstream infection (BSI) assay that aims to provide identification of pathogens and drug resistance within hours, directly from blood samples.